ES2472040B1 - Uso de paricalcitol en el tratamiento de la anemia inflamatoria - Google Patents
Uso de paricalcitol en el tratamiento de la anemia inflamatoria Download PDFInfo
- Publication number
- ES2472040B1 ES2472040B1 ES201430177A ES201430177A ES2472040B1 ES 2472040 B1 ES2472040 B1 ES 2472040B1 ES 201430177 A ES201430177 A ES 201430177A ES 201430177 A ES201430177 A ES 201430177A ES 2472040 B1 ES2472040 B1 ES 2472040B1
- Authority
- ES
- Spain
- Prior art keywords
- paricalcitol
- treatment
- inflammatory anemia
- stimulating agents
- erythropoiesis stimulating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Uso de paricalcitol en el tratamiento de la anemia inflamatoria.#La presente invención describe el uso de paricalcitol, análogo sintético de la vitamina D, en el tratamiento de la anemia inflamatoria, preferentemente en combinación con agentes estimuladores de la eritropoyesis. El uso del paricalcitol para el tratamiento de dicha patología está asociado a un menor requerimiento de agentes estimuladores de la eritropoyesis, a una mejor utilización del hierro y a un incremento en los niveles de eritropoyetina plasmática, por parte de dichos pacientes. La presente invención describe además composiciones farmacéuticas que comprenden paricalcitol en combinación con agentes estimuladores de la eritropoyesis y excipientes farmacéuticamente aceptables, así como el uso de las mismas como medicamentos para el tratamiento de la anemia inflamatoria.
Description
Claims (1)
-
imagen1 imagen2
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201430177A ES2472040B1 (es) | 2014-02-11 | 2014-02-11 | Uso de paricalcitol en el tratamiento de la anemia inflamatoria |
CN201580007824.4A CN106061498B (zh) | 2014-02-11 | 2015-01-16 | 帕立骨化醇在炎性贫血的治疗中的用途 |
CA2938057A CA2938057A1 (en) | 2014-02-11 | 2015-01-16 | Use of paricalcitol in the treatment of inflammatory anaemia |
ES15702156T ES2728158T3 (es) | 2014-02-11 | 2015-01-16 | Paricalcitol para uso en el tratamiento de la anemia inflamatoria |
DK15702156.9T DK3104872T3 (da) | 2014-02-11 | 2015-01-16 | Paricalcitol til anvendelse ved behandling af inflammatorisk |
KR1020167023202A KR20160113664A (ko) | 2014-02-11 | 2015-01-16 | 염증성 빈혈 치료에 사용되는 파리칼시톨의 용도 |
PT15702156T PT3104872T (pt) | 2014-02-11 | 2015-01-16 | Paricalcitol para uso no tratamento de anemia inflamatória |
RU2016131412A RU2016131412A (ru) | 2014-02-11 | 2015-01-16 | Применение парикальцитола для лечения воспалительной анемии |
US15/117,896 US11464791B2 (en) | 2014-02-11 | 2015-01-16 | Use of paricalcitol in the treatment of inflammatory anaemia |
AU2015217956A AU2015217956B2 (en) | 2014-02-11 | 2015-01-16 | Use of paricalcitol in the treatment of inflammatory anaemia |
EP15702156.9A EP3104872B1 (en) | 2014-02-11 | 2015-01-16 | Paricalcitol for use in the treatment of inflammatory anaemia |
JP2016552329A JP2017512753A (ja) | 2014-02-11 | 2015-01-16 | 炎症性貧血の処置におけるパリカルシトールの使用 |
MX2016010104A MX365096B (es) | 2014-02-11 | 2015-01-16 | Uso de paricalcitol en el tratamiento de la anemia inflamatoria. |
PCT/EP2015/050817 WO2015121022A1 (en) | 2014-02-11 | 2015-01-16 | Use of paricalcitol in the treatment of inflammatory anaemia |
UY35989A UY35989A (es) | 2014-02-11 | 2015-02-10 | Uso de paricalcitol en el tratamiento de la anemia inflamatoria |
ARP150100380A AR099330A1 (es) | 2014-02-11 | 2015-02-10 | Uso de paricalcitol en el tratamiento de la anemia inflamatoria |
IL247207A IL247207B (en) | 2014-02-11 | 2016-08-10 | Use of pericalcitol in the treatment of inflammatory anemia |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201430177A ES2472040B1 (es) | 2014-02-11 | 2014-02-11 | Uso de paricalcitol en el tratamiento de la anemia inflamatoria |
Publications (3)
Publication Number | Publication Date |
---|---|
ES2472040A2 ES2472040A2 (es) | 2014-06-27 |
ES2472040R1 ES2472040R1 (es) | 2014-09-18 |
ES2472040B1 true ES2472040B1 (es) | 2015-07-01 |
Family
ID=51205045
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES201430177A Expired - Fee Related ES2472040B1 (es) | 2014-02-11 | 2014-02-11 | Uso de paricalcitol en el tratamiento de la anemia inflamatoria |
ES15702156T Active ES2728158T3 (es) | 2014-02-11 | 2015-01-16 | Paricalcitol para uso en el tratamiento de la anemia inflamatoria |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES15702156T Active ES2728158T3 (es) | 2014-02-11 | 2015-01-16 | Paricalcitol para uso en el tratamiento de la anemia inflamatoria |
Country Status (16)
Country | Link |
---|---|
US (1) | US11464791B2 (es) |
EP (1) | EP3104872B1 (es) |
JP (1) | JP2017512753A (es) |
KR (1) | KR20160113664A (es) |
CN (1) | CN106061498B (es) |
AR (1) | AR099330A1 (es) |
AU (1) | AU2015217956B2 (es) |
CA (1) | CA2938057A1 (es) |
DK (1) | DK3104872T3 (es) |
ES (2) | ES2472040B1 (es) |
IL (1) | IL247207B (es) |
MX (1) | MX365096B (es) |
PT (1) | PT3104872T (es) |
RU (1) | RU2016131412A (es) |
UY (1) | UY35989A (es) |
WO (1) | WO2015121022A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022030665A1 (ko) * | 2020-08-05 | 2022-02-10 | 경상대학교병원 | 조영제-유발 신독성 예방 또는 치료용 약학 조성물 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004062620A2 (en) * | 2003-01-13 | 2004-07-29 | Cedars-Sinai Medical Center | Paricalcitol as a chemotherapeutic agent |
EP1737888A2 (en) * | 2004-04-23 | 2007-01-03 | Cambridge Antibody Technology LTD | Erythropoietin protein variants |
CA2674368A1 (en) * | 2007-01-10 | 2008-07-17 | Edison Pharmaceuticals, Inc. | Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity |
CN102772364B (zh) * | 2011-05-13 | 2015-12-02 | 重庆华邦制药有限公司 | 帕立骨化醇的脂肪乳及其制剂和制备方法 |
-
2014
- 2014-02-11 ES ES201430177A patent/ES2472040B1/es not_active Expired - Fee Related
-
2015
- 2015-01-16 CN CN201580007824.4A patent/CN106061498B/zh active Active
- 2015-01-16 US US15/117,896 patent/US11464791B2/en active Active
- 2015-01-16 KR KR1020167023202A patent/KR20160113664A/ko not_active Application Discontinuation
- 2015-01-16 CA CA2938057A patent/CA2938057A1/en not_active Abandoned
- 2015-01-16 JP JP2016552329A patent/JP2017512753A/ja active Pending
- 2015-01-16 PT PT15702156T patent/PT3104872T/pt unknown
- 2015-01-16 AU AU2015217956A patent/AU2015217956B2/en active Active
- 2015-01-16 DK DK15702156.9T patent/DK3104872T3/da active
- 2015-01-16 ES ES15702156T patent/ES2728158T3/es active Active
- 2015-01-16 WO PCT/EP2015/050817 patent/WO2015121022A1/en active Application Filing
- 2015-01-16 RU RU2016131412A patent/RU2016131412A/ru unknown
- 2015-01-16 EP EP15702156.9A patent/EP3104872B1/en active Active
- 2015-01-16 MX MX2016010104A patent/MX365096B/es active IP Right Grant
- 2015-02-10 UY UY35989A patent/UY35989A/es not_active Application Discontinuation
- 2015-02-10 AR ARP150100380A patent/AR099330A1/es unknown
-
2016
- 2016-08-10 IL IL247207A patent/IL247207B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
IL247207B (en) | 2020-02-27 |
DK3104872T3 (da) | 2019-06-17 |
PT3104872T (pt) | 2019-06-11 |
MX365096B (es) | 2019-05-22 |
ES2472040R1 (es) | 2014-09-18 |
CN106061498A (zh) | 2016-10-26 |
CA2938057A1 (en) | 2015-08-20 |
EP3104872B1 (en) | 2019-03-13 |
IL247207A0 (en) | 2016-09-29 |
CN106061498B (zh) | 2019-12-06 |
US20160367571A1 (en) | 2016-12-22 |
RU2016131412A (ru) | 2018-03-15 |
MX2016010104A (es) | 2017-01-06 |
WO2015121022A1 (en) | 2015-08-20 |
AU2015217956B2 (en) | 2019-04-04 |
UY35989A (es) | 2015-03-27 |
ES2728158T3 (es) | 2019-10-22 |
US11464791B2 (en) | 2022-10-11 |
ES2472040A2 (es) | 2014-06-27 |
AR099330A1 (es) | 2016-07-13 |
AU2015217956A1 (en) | 2016-08-25 |
EP3104872A1 (en) | 2016-12-21 |
KR20160113664A (ko) | 2016-09-30 |
JP2017512753A (ja) | 2017-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
DOP2018000297A (es) | Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo | |
UY37098A (es) | Moduladores de ror-gamma | |
UY35916A (es) | Compuestos tricíclicos como agentes antineoplásicos inhibidores del bromodominio | |
BR112016020618A8 (pt) | oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido | |
ECSP20046463A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
CL2016001918A1 (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
CO2017002472A2 (es) | Formulación de acetato de abiraterona | |
MX2016008429A (es) | Derivado de piranocromenil fenol, y composicion farmaceutica para tratar un sindrome metabolico o enfermedad inflamatoria. | |
ECSP17044282A (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
AR094707A1 (es) | Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2 | |
ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
BR112018072113A2 (pt) | excipiente à base de proteínas para ingredientes farmacêuticos ativos | |
CO2017006958A2 (es) | Formulaciones farmacéuticas que comprenden cangrelor de alta pureza y métodos para la preparación y uso de los mismos | |
DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
CL2016000884A1 (es) | Derivados de piperazina y su uso como medicamento. | |
CL2012003006A1 (es) | Compuestos derivados de lactonas esteroideas insaturadas en la posicion 7(8) y sus sales y estereoisomeros farmaceuticamente aceptables; composicion farmaceutica que las comprende; y su uso para el tratamiento del cancer. | |
ECSP16086232A (es) | (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
ES2811674R1 (es) | Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria | |
IT201600081379A1 (it) | Composizione farmaceutica per uso nel trattamento delle patologie prostatiche. | |
ECSP16086196A (es) | Sales farmacéuticamente aceptables de enantiomeros de pirlindole para uso en medicina | |
ES2611776T3 (es) | Uso de sales de tungsteno (VI) para el tratamiento de la esterilidad femenina en mamíferos no diabéticos | |
CO2018008626A2 (es) | Formulaciones de oritavancina | |
ES2472040B1 (es) | Uso de paricalcitol en el tratamiento de la anemia inflamatoria | |
UY36732A (es) | Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 2472040 Country of ref document: ES Kind code of ref document: B1 Effective date: 20150701 |
|
FD2A | Announcement of lapse in spain |
Effective date: 20211004 |